Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ: EWTX )

24.58 -0.70 (-2.77%)
Streaming Delayed Price Updated: 12:54 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Dow Eyes Worst Losing Streak Since 2018
The Nasdaq Composite is up triple digits midday, hitting fresh record highs as it looks to build off a fourth-straight weekly win. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
Edgewise Therapeutics reports promising Phase 2 results for sevasemten, showing reduced muscle damage and well-tolerated safety in Becker muscular dystrophy. 
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Edgewise Therapeutics: Q4 Earnings Insights
Via Benzinga
How Is The Market Feeling About Edgewise Therapeutics?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
Via Benzinga
Exposures Fossil Fuels
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
One of the biopharma company's heart drugs performs as well as initially hoped. 
Via The Motley Fool
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT... 
Via Benzinga
Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. 
Via Investor's Business Daily
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
7 Small-Cap Stocks to Buy for Large-Scale Gains
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling. 
Via InvestorPlace
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? 
Via Investor's Business Daily
Topics Government
Exposures Political
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
Insider Favorites: 7 Stocks with Bullish Buying Signals
Although you’ll still want to conduct your due diligence, following the smart money into these insider favorite stocks is tempting. 
Via InvestorPlace
Insiders Buying Edgewise Therapeutics And 2 Other Stocks
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
What's Going On With Edgewise Therapeutics Stock?
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are trading higher Friday after the company announced the pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share. 
Via Benzinga
World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation (NASDAQ: WRLD) rose sharply during Friday’s session following upbeat... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Analysts have high hopes for these three innovation companies in 2024. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.